Audit: QRS - Mexidol for Health & Longevity

Audit conducted on 11/10/2026 03:39 using AI4L / Opus 5.5

Iterations

Summary

Items	Count
Total	94
Passed	88
Failed	0
N/A	6
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Protocol, contraindications, interactions, tiers, markers and cadence all trace to ER text (e.g., action_2_sub = ER Therapeutic Protocol line 353; marker rows = ER table lines 409-413; anxiety questionnaire = ER line 403/405)
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	“(theoretical)” kept on ABCB1, OTC sedatives, calming supplements, succinate and antioxidant items; “only intravenous courses were tested” kept (time_3_sub); “possibly lowered” kept for CYP3A4
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Interaction verdicts (Caution/Monitor) and contraindications match ER wording; liver/kidney thresholds stay labeled as trial exclusions
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Contraindications come from ‘Populations who should avoid Mexidol’; risk-modifying factors (e.g., sulfite-sensitive asthma) are not surfaced as risks or contraindications
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, NCT IDs or trial names; Cytoflavin and COVID-19 appear in the ER for the same facts
1.6	The QRS does not introduce new attributions.	🟢

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢
2.4	The QRS avoids language that implies medical or clinical advice	🟢
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms (CYP3A4, ABCB1) carry the ER’s plain-language glosses
2.8	Information is presented in a concise and very compact manner	🟢
2.9	It DOES NOT address the reader directly	🟢
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	At-a-glance states the healthy-adult gap (‘Unproven in healthy adults; slower aging rests on animal studies alone’)
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	No ‘anti-aging’ wording
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt.	🟢	Routes given as ‘intravenous’/’orally’; no pill/shot/by-mouth phrasing

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment” Gate headings: “Contraindications”, “Key Interactions” Tier labels: “High”, “Medium”, “Low”, “Speculative” Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All fixed headings, gate heads, tier labels and table headers identical to template
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All template data-qrs-var spans present (marker_# expanded to 1-6, qualitative_item_# to 1-5)
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	Diff vs template: head/CSS/footer and website spans unchanged; only metadata and variables filled

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	🟢	No non-tiered ER section is empty; empty High risk tier handled per 13.5
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	Protocol labels (Label oral course, Trial sequential regimen, Lower oral dose), interaction labels and ‘Time to effect’ use ER bold labels verbatim
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji indicators
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Content condensed (interactions reduced to label plus verdict, benefits to short descriptors)

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Metadata comment at line 2, directly after <!doctype html>
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration is quoted; it contains a colon
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	26.10.8
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	2026-1011-0313
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	Opus
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	Opus 5.5
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	‘Mexidol for Health & Longevity - Quick Reference Sheet’
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	10/11/2026
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Opus 5.5
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] opens by saying what the intervention is — its kind (e.g., dietary supplement, prescription medication, peptide, plant, procedure, practice) — and what it is used for, in plain language, before any verdict on the evidence	🟢	Opens with ‘a Russian prescription medicine … used mainly for stroke, brain blood-flow disease and anxiety’
7.2	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢
7.3	[at_a_glance] is no longer than 70 words	🟢	69 words
7.4	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Each fact maps to ER Conclusion paragraphs 1-4
7.5	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢
7.6	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢
7.7	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢
8.2	[stop_items] represent the Contraindications from the ER	🟢	All six ER ‘Populations who should avoid Mexidol’ items present
8.3	Individual [stop_items] are formatted as <li></li>	🟢
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	ALT/AST ≥2×, bilirubin ≥1.5×, creatinine clearance <50 mL/min, 250 mg tablets, tablet forms preserved
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	🟢	No ranking notation in ER
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	Section populated
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	Section not empty

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	Ten ER interaction items with a verdict carried; ‘No interaction found’ items (BP/antiplatelet, clot-dissolving, alcohol) omitted as non-interactions
9.3	Individual [caution_items] are formatted as <li></li>	🟢
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Example drug lists and ER glosses preserved
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	🟢	No ranking notation in ER
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	Section populated
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	Section not empty

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	ER provides more than three actionable aspects
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Cognition/brain blood-flow trial (MEMO), fatigue, diabetic nerve symptoms
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	High, High, Medium order
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	Three time-to-effect aspects available
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	ER provides time-to-effect information

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four benefit tiers have items

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	risks_high span set to display: none

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	ALT, AST, serum creatinine, LDL, MoCA and anxiety questionnaire score listed
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All five ER qualitative markers listed verbatim

Issues 11/10/2026 03:39

Pass rate 100.00%. No issues found.

Issues 11/10/2026 03:36

1. 2.7 — Unexplained enzyme jargon in risks: The Risks Speculative tier (line 586) lists “monoamine oxidase effects”, a specialist term left untranslated although the sheet otherwise renders ER headings in plain language.

Fixes 11/10/2026 03:36

1. 2.7 — Plain-language enzyme risk wording: Replaced “monoamine oxidase effects” in the Risks Speculative tier with “effects on enzymes that break down serotonin and dopamine”, matching the ER definition.

Issues 11/10/2026 03:32

1. 14.2 — Anxiety score marker missing: The ER Monitoring section (lines 403–405) names a brief anxiety questionnaire at baseline and anxiety scores at each course end, and the QRS cadence (line 662) cites “anxiety scores”, yet the Monitoring table (lines 603–657) has no anxiety-score row.

Fixes 11/10/2026 03:32

1. 14.2 — Anxiety score marker added: Added a sixth Monitoring row “Anxiety questionnaire score” with target “Track change from own baseline” and why “Expected to change”, matching the ER baseline and course-end anxiety scoring.

Issues 11/10/2026 03:28

1. 4.5 — Content exceeds one A4 page: The sheet carries ~690 visible words: 10 Key Interactions items (lines 555-564), a 9-item Medium benefits line (line 525), long protocol subs (lines 461, 489) and a ~300-character monitoring cadence (line 662), which together extend well beyond one A4 page instead of being condensed.

Fixes 11/10/2026 03:28

1. 4.5 — Condensed monitoring cadence: Shortened the cadence text (line 662) from ~300 to ~250 characters, keeping all intervals (“at the end of each course” → “course end”, “reviewed daily during the first week” → “daily in week one”).
2. 4.5 — Condensed liver contraindication threshold: Replaced “at or above 2 times the upper limit of normal, or bilirubin at or above 1.5 times” with “≥2× upper limit of normal, or bilirubin ≥1.5×”, keeping both thresholds.
3. 4.5 — Condensed Medium benefits line: Replaced “low-density lipoprotein cholesterol” with “LDL cholesterol” and “attention deficit hyperactivity symptoms” with “ADHD symptoms”.

Issues 11/10/2026 03:25

1. 2.7 — Unexplained clinical jargon: Benefits use “cerebrovascular disease” (line 522) and “myocardial infarction” (line 525) although the ER gives plain-language equivalents (“brain blood-flow disease”, “heart attack”); time_1_label (line 483) uses “Brain-Ischemia”.
2. 4.2 / 4.3 — Invented time-to-effect label: time_1_label “Effects in Brain-Ischemia Trial” (line 483) is not in the ER; the source bullet’s bold label is “Time to effect” (ER Practical Considerations).

Fixes 11/10/2026 03:25

1. 2.7 — Plain-language benefit terms: Replaced “cerebrovascular disease” with “brain blood-flow disease” and “myocardial infarction” with “heart attack” in Benefits; time_1_sub now names the trial context in plain language (“in a brain blood-flow trial”) instead of “Brain-Ischemia”.
2. 4.2 / 4.3 — Verbatim time-to-effect label: Changed time_1_label from “Effects in Brain-Ischemia Trial” to the ER bold label “Time to effect”.

Issues 11/10/2026 03:23

1. 1.1 — Time-to-effect label over-attributed: time_1_label (QRS line 483) names “Improved Cognition in Cerebrovascular Disease”, but the ER’s time-to-effect statement (line 386) says only that “differences from placebo” in the MEMO brain-ischemia trial appeared by day 14, without naming cognition.

Fixes 11/10/2026 03:23

1. 1.1 — Time-to-effect label over-attributed: Changed time_1_label from “Improved Cognition in Cerebrovascular Disease” to “Effects in Brain-Ischemia Trial”, matching the ER statement that only names differences from placebo in the brain-ischemia trial.

Issues 11/10/2026 03:19

1. 2.7 — Unexplained liver-enzyme acronyms: The acute liver dysfunction contraindication (line 543) uses “ALT or AST” without plain-language context; the ER identifies them as liver enzymes.
2. 4.2 — Interaction label not verbatim: The succinate interaction label (line 563) drops “agents that shift cellular energy use” from the ER bold label “Succinate and metabolic-modulator products (agents that shift cellular energy use; succinic acid, Cytoflavin, meldonium)”.
3. 7.2 — Lede omits Conclusion safety: The at-a-glance text (line 433) leaves out the Conclusion’s safety paragraph — side effects similar to placebo, strengthening of sedatives and calming medicines, and unknown safety over years of continuous use.

Fixes 11/10/2026 03:19

1. 2.7 — Liver-enzyme acronyms explained: Changed “trial exclusion: ALT or AST” to “trial exclusion: liver enzymes ALT or AST” in the acute liver dysfunction contraindication.
2. 4.2 — Verbatim interaction label restored: Restored the full ER bold label “Succinate and metabolic-modulator products (agents that shift cellular energy use; succinic acid, Cytoflavin, meldonium)”.
3. 7.2 — Safety added to lede: Added “Side effects resembled placebo, but it can strengthen sedatives; long-term safety is unknown” to the at-a-glance text and tightened other wording to stay at 69 words.

Issues 11/10/2026 03:18

1. 1.1 / 7.4 — Trial funding claim broadened: At a Glance (line 433) says “Most controlled trials were manufacturer-funded”, while the ER Conclusion (ER line 444) states “Most placebo-controlled trials were paid for by the manufacturer”.
2. 2.7 — CYP3A4 jargon unexplained: Key Interactions (line 559) shows “Drugs cleared by CYP3A4” without the ER’s plain-language gloss “a liver enzyme that breaks down many drugs” (ER line 316).
3. 12.4 — Parenthetical kept in benefits: benefits_high (line 522) retains the parenthetical “(asthenia)” after “less fatigue”.

Fixes 11/10/2026 03:18

1. 1.1 / 7.4 — Trial funding claim broadened: Changed “Most controlled trials were manufacturer-funded” to “Most placebo-controlled trials were manufacturer-funded” in At a Glance, matching the ER Conclusion.
2. 2.7 — CYP3A4 jargon unexplained: Restored the ER gloss in the Key Interactions label: “Drugs cleared by CYP3A4 (a liver enzyme that breaks down many drugs; simvastatin, apixaban, tacrolimus)”.
3. 12.4 — Parenthetical kept in benefits: Removed “(asthenia)” from benefits_high, leaving “less fatigue”.